CarnoSyn® Brands Unveils TriBsyn™ - “The World’s First Paresthesia-Free Beta-Alanine Powder”
Rhea-AI Summary
Natural Alternatives International (NAI) has unveiled TriBsyn™, a revolutionary carnosine booster under its CarnoSyn® Brands portfolio. This groundbreaking product utilizes CarnoSyn® beta-alanine and patent-pending technology to increase beta-alanine bioavailability and absorption while eliminating paresthesia, a common side effect. TriBsyn™ improves beta-alanine absorption by more than four times compared to conventional forms, allowing for lower dosages and increased formulation flexibility.
The product aims to support general wellness, including cognitive performance, muscle function in older adults, and slowing age-related health decline. NAI plans to launch TriBsyn™ commercially at the 46th ESPEN Congress in Milan, Italy, in September. The company expects this innovation to strengthen its presence in dietary supplement categories and fortified and medical foods markets, particularly targeting the aging population and those with plant-based diets.
Positive
- Launch of TriBsyn™, a new carnosine booster with enhanced beta-alanine bioavailability
- Elimination of paresthesia side effect associated with beta-alanine supplementation
- Improved absorption of beta-alanine by more than four times compared to conventional forms
- Potential to expand market reach to older adults, vegetarians, and vegans
- Expected strengthening of NAI's presence in dietary supplement and fortified foods markets
Negative
- None.
Insights
The introduction of TriBsyn™ represents a significant advancement in beta-alanine supplementation. By eliminating paresthesia, a common side effect, it potentially expands the market to previously untapped demographics such as older adults and those following plant-based diets. The improved bioavailability, with a
However, it's important to note that while the product shows promise, its commercial success remains uncertain. The market's reception and the product's ability to deliver on its claims in real-world settings will be critical factors to watch. Additionally, the impact on NAI's financials will depend on pricing strategy, production costs and market penetration rates, which are not disclosed in this announcement.
The launch of TriBsyn™ could potentially disrupt the beta-alanine supplement market. By addressing the paresthesia issue, NAI is targeting a broader consumer base, including older adults and plant-based diet followers. This strategic move aligns with the growing trend towards healthy aging and wellness solutions.
However, success will hinge on several factors:
- Pricing strategy in a competitive supplement market
- Effectiveness of marketing to new demographics
- Acceptance by healthcare professionals and nutritionists
While the innovation is promising, investors should closely monitor initial sales figures and consumer feedback post-launch to gauge market acceptance and potential revenue impact.
CARLSBAD, Calif., Aug. 07, 2024 (GLOBE NEWSWIRE) -- Exclusively from Natural Alternatives International, Inc. (NAI), CarnoSyn® Brands portfolio of patented ingredients presents TriBsyn™, a groundbreaking new carnosine booster utilizing CarnoSyn® beta-alanine and patent-pending technology to increase beta-alanine bioavailability and absorption while effectively eliminating beta-alanine related paresthesia.
The proprietary TriBsyn™ formulation successfully removes the common paresthesia sensation associated with efficacious dosages of beta-alanine, creating a brand-new opportunity to reach untapped consumers from older adults to vegetarians and vegans.
Increased carnosine levels have been scientifically proven to provide a significant range of support for general wellness, including:
- Bolstering cognitive performance and improving mental fatigue
- Increasing both muscle function and quality in older adults
- Slowing the process of age-related health and mental decline
In clinical trials, results showed the elimination of paresthesia and an increased pharmacokinetic efficiency, confirming TriBsyn’s™ enhanced delivery and exceptional bioavailability—improving the absorption of beta-alanine by more than four times compared to conventional beta-alanine. The increased efficiency allows for product formulations with significantly less beta-alanine, thereby improving formulation flexibility for various delivery systems.
“After extensive research and trials, we are proud to announce TriBsyn™, which contains CarnoSyn®, the only beta-alanine approved by the FDA under NDI status,” said Aaron Starr, Vice President, CarnoSyn® Brands. “With the innovation of a paresthesia-free beta-alanine, TriBsyn™ sets a new standard in beta-alanine supplementation, ensuring that users can experience the full range of health benefits without the paresthesia or ‘tingling’ often experienced as a side effect. We eagerly anticipate the commercial launch of TriBsyn™ at our first industry event in September, at the 46th ESPEN Congress on Clinical Nutrition & Metabolism in Milan, Italy.”
Ken Wolf, President of NAI shared, “TriBsyn’s™ launch will bolster our presence in a plethora of dietary supplement categories as well as fortified and medical foods. There is an evolving need and growing demand for healthy aging and wellness solutions—particularly for the aging population and those with plant-based diets. We look forward to sharing this revolutionary new product with our existing customers as well as creating a new customer following.”
To learn more about TriBsyn™ visit www.tribsyn.com.
About CarnoSyn® Brands:
CarnoSyn® Brands feature three clinically studied, patented ingredients available exclusively from Natural Alternatives International, Inc.: CarnoSyn® instant release beta-alanine powder, SR CarnoSyn® sustained release beta-alanine tablets, and TriBsyn™ powder. In 2019, CarnoSyn® beta-alanine successfully obtained NDI status from the FDA and received Self-Affirmed GRAS (Generally Recognized as Safe) status. SR CarnoSyn®, an advanced delivery form of CarnoSyn®, received GRAS affirmation in 2017. The new “paresthesia-free” TriBsyn™ powder allows NAI to broaden their product offerings within the dietary supplement category, including medical and other fortified food products. To learn more about SR CarnoSyn® in active nutrition and wellness, visit www.srcarnosyn.com. For more information about the latest innovation, TriBsyn™, visit www.tribsyn.com.
About NAI:
NAI, headquartered in Carlsbad, California, is a leading formulator, manufacturer and marketer of nutritional supplements and provides strategic partnering services to its customers. NAI’s comprehensive partnership approach offers a wide range of innovative nutritional products and services to clients including scientific research, proprietary ingredients, customer-specific nutritional product formulation, product testing and evaluation, marketing management and support, packaging and delivery system design, regulatory review, and international product registration assistance. For more information about NAI, please visit www.nai-online.com.
Contact:
Renee Michaelson
Director of Global Marketing
NAI/CarnoSyn® Brands
(760) 736-7700
info@nai-online.com
FAQ
What is TriBsyn™ and how does it differ from regular beta-alanine supplements?
How much more effective is TriBsyn™ compared to conventional beta-alanine?
When and where will Natural Alternatives International (NAII) launch TriBsyn™?
What are the potential health benefits of TriBsyn™?
